Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03450109 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer
A Phase 1 study, sponsored by Luye Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03450109 is a Phase 1 study that has completed, run by Luye Pharma Group. The registered enrollment target is 19 participants.
The verdict
NCT03450109, a Phase 1 study, has completed, sponsored by Luye Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
A phase I, randomized, open-label and active-control study to assess the PK, PD and safety profiles of LY01005 versus goserelin comparator to be conducted in the USA.
Interventions
- DRUG Zoladex
- DRUG LY01005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-12-22 |
| Est. Completion | 2018-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03450109
The ClinicalTrials.gov registry entry for NCT03450109 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Luye Pharma Group, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zoladex is the first listed.
NCT03450109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03450109 about?
NCT03450109 is a clinical study titled "A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer". A phase I, randomized, open-label and active-control study to assess the PK, PD and safety profiles of LY01005 versus goserelin comparator to be conducted in the USA.
What is the current status of trial NCT03450109?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2017-12-22. Estimated completion is 2018-10-30.
What interventions are being tested in trial NCT03450109?
The interventions under investigation include: Zoladex (DRUG), LY01005 (DRUG).
Who is sponsoring clinical trial NCT03450109?
This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.